Stem Cell Research Market to 2017 - Strong Pipeline, High Unmet Needs in Chronic Diseases and Favorable Government Policies to Boost Stem Cell R&D


Summary

Company, the leading business intelligence provider, has released its latest research “Stem Cell Research Market to 2017 - Strong Pipeline, High Unmet Needs in Chronic Diseases and Favorable Government Policies to Boost Stem Cell R&D”. The report provides an in-depth analysis on global stem cell research and development. The report suggests investment decisions in stem cell research by providing trends and information on pipelines, federal spending, venture capitalist perspective, country regulations, competitive landscape and market potential. It also provides an analysis on the current investments in various stem cell research segments. In addition to this, the report covers market drivers and challenges for stem cell research and development market.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Company’s team of industry experts.

Company analysis finds that stem cell therapies have immense market potential driven by strong pipeline that caters to high unmet needs. Increasing investment and supportive regulatory environment in key geographies will help the stem cells industry to realize its full potential. Stem cell therapies high market potential is based on their unique ability to offer curative treatment in comparison to the symptomatic treatment offered by conventional treatments. From a commercial perspective, many diseases that arise as a result of irreversible damage to specialized cell types currently have large unmet needs that cannot be served based on conventional pharmaceutical and biotech research. Not serving these unmet needs results in loss of growth opportunities for the pharmaceutical industry. Stem cell research is a technology that has the potential to serve these unmet needs by providing alternatives to conventional pharmaceutical and biotech research which are targeted more at the symptoms than at the cause.

Strategic partnerships between pharmaceutical companies and stem cell research companies are boosting stem cell research and development. Almost 90% of the drugs in clinical trials fail due to factors such as lack of effectiveness and adverse side effects of the drug. Usually animal or tumor cells are being used and this leads to jury-rigged tests. Hence all major pharmaceutical companies are looking forward for new technologies that increase the possibility to launch new therapies in the market place. At present, there has been a spur in investments from pharmaceutical companies into stem cell research through strategic partnerships with stem cell research companies. Major pharmaceutical companies have planned and aligned their objectives to enter the stem cell market in the next 3-5 years, with a few strategic partnerships already formed between pharmaceutical companies and stem cell research based companies. Pharmaceutical companies are also exploring various methods where stem cells could be utilized in drug discovery process to accelerate the discovery of novel drug molecules.

Scope

- Country analysis of regulatory framework, investments, research clusters and overall support including the US, the UK, Germany, France, Japan, China, India, Singapore, Canada, and Australia.
- Investment Analysis in leading geographies.
- In-depth information and analysis on the pipeline products expected to bring a shift to the market positions of the leading manufacturers.
- Market characterization data for stem cell research including population size, market potential, NIH funding, technology adoption framework and business models.
- Key drivers and restraints that have a significant impact on the market.
- Competitive landscape of global stem cell research including benchmarking of the leading companies. The key companies discussed in this report are Aastrom Biosciences, Athersys, Bioheart, Aldagen, Mesoblast, Geron Corporation, Advanced Cell Technology, Cytori Therapeutics, Pluristem Therapeutics, Medistem, NeoStem, Helix Therapeutics and StemCells Inc.
- Key M&A activities, licensing agreements, that have taken place between stem cell companies in 2011 till date.

Reasons to buy

- Build effective strategies to launch pipeline products by identifying the latest regulatory developments in the leading geographies
- Develop market-entry and market expansion strategies by identifying the geographic markets poised for strong growth
- Exploit in-licensing and out-licensing opportunities by identifying products that could fill their portfolio gaps
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships
- Develop key strategic initiatives by studying the key strategies of top competitors
- Reinforce R&D pipelines by identifying licensing strategies for acquiring new delivery mechanisms that have more efficiency and better safety

1 Table of Contents 4
1.1 List of Tables 7
1.2 List of Figures 8
2 Stem Cell Research Market to 2017 - Introduction 10
2.1 GBI Research Report Guidance 11
3 Stem Cell Research Market to 2017- Market Overview 12
3.1 Stem Cell Research – An Introduction 12
3.2 Types of Stem Cell Research 12
3.3 Current Utilization of Different Types of Stem Cells 14
3.4 Unmet Needs 14
3.4.1 Applications of Stem Cell Research 18
4 Stem Cell Research Market to 2017- Market Characterization 20
4.1 Stem Cell Market – An Introduction 20
4.2 Market Sizing 21
4.3 Therapy Cost 24
4.4 Technology Adoption Framework 25
4.5 Types of Business Models 26
4.6 Market Drivers 27
4.6.1 Immense Market Opportunity for Stem Cell Research for Certain Disorders with High Unmet Need in Terms of Safe and Efficacious Drugs 27
4.6.2 Encouraging Political Environment on Embryonic Stem Cell Research in the US 28
4.6.3 Advances in Induced Pluripotent Stem Cells (iPSC) can Decrease Dependency on Embryonic Stem Cells and Increase the Acceptance of Stem Cell Therapy 29
4.7 Market Barriers & Challenges 30
4.7.1 High Cost of Research Demands High Investments in the Stem Cell Research and Development 30
4.7.2 Uncertain Reimbursement Scenario for Stem Cell Therapies Due to High Treatment Cost and Unclear Cost-Benefit Ratio 31
4.7.3 Ethical, Legal and Social Issues Continue to Remain a Challenge – Albeit with Reduced Impact 32
4.7.4 Management of Best Scientific Talent for Stem Cell Research Based Companies Remains a Key Area of Focus to Sustain High Quality Research 33
4.8 Stem Cell Research and Development - Market Trends 34
4.8.1 Booming Stem Cell Tourism is a Potential Opportunity for Countries to Attract Investments 34
4.8.2 ASLAP Analysis of Stem Cell Tourism 35
4.8.3 Federal Funding Support Improves the Stem Cell Research Environment 37
4.8.4 Increasing Entry of Pharmaceutical Companies Boosts Stem Cell Research & Development 38
4.8.5 PESTLE Analysis of Stem Cell Research 39
4.8.6 SWOT Analysis of Stem Cell Research & Development 41
4.9 Market Analysis 43
5 Stem Cell Research Market to 2017 - Pipeline Analysis 45
5.1 Discovery 45
5.2 IND Filed 46
5.3 Pre-Clinical 46
5.4 Phase I 49
5.5 Phase II 54
5.6 Phase III 76
6 Stem Cell Research Market to 2017 - Investment Trends 81
6.1 Investor’s Perspective on Stem Cell Research 81
6.1.1 Status of Research 82
6.1.2 Regulatory Position 82
6.1.3 Clinical Development 82
6.1.4 Commercial Models 82
6.1.5 Patent Policy 83
6.2 NIH Spending in Stem Cell Research and Development is Increasing and is Supportive 83
6.2.1 NIH Spending by Therapeutic Areas 84
6.2.2 High Budget Projects Funded by NIH 110
6.3 BBSRC Funding in Stem Cell Research 111
7 Stem Cell Research Market to 2017 - Geographical Trends 113
7.1 Stem Cell Companies by Geographic Regions 113
7.2 The US 115
7.3 The UK 116
7.4 China 117
7.5 Netherlands 118
7.6 Singapore 119
7.7 South Korea 120
7.8 Japan 121
7.9 India 122
7.10 Sweden 123
7.11 Denmark 124
7.12 France 125
7.13 Germany 126
7.14 Israel 127
7.15 Australia 128
7.16 Canada 129
7.17 Czech Republic 130
8 Stem Cell Research Market to 2017 - Mergers and Acquisitions 131
8.1 Mergers and Acquisitions 131
8.1.1 Overview 131
8.1.2 Segmentation by Type 132
8.1.3 Segmentation by Region 134
8.2 Licensing Agreements and Co-Development 136
8.2.1 Segmentation by Region 136
8.2.2 Segmentation by Deal Type 138
9 Stem Cell Research Market to 2017 - Company Profiles 140
9.1 Aastrom Biosciences 140
9.2 Athersys Inc. 141
9.3 Osiris Therapeutics 142
9.4 Bioheart 143
9.5 Aldagen 144
9.6 Mesoblast 145
9.7 Geron 146
9.8 Advanced Cell Technology 147
9.9 Cytori Therapeutics 148
9.10 Pluristem Therapeutics 149
9.11 Medistem 150
9.12 NeoStem 151
9.13 Helix Therapeutics 152
9.14 StemCells Inc. 153
10 Stem Cell Research Market to 2017- University Profiles 154
10.1 University of California, San Francisco 154
10.2 University of Washington 155
11 Stem Cell Research Market to 2017 - Conclusion 156
12 Stem Cell Research Market to 2017- Appendix 157
12.1 Market Definitions 157
12.2 Abbreviations 157
12.3 Methodology 157
12.3.1 Coverage 157
12.3.2 Secondary Research 158
12.3.3 Primary Research 158
12.3.4 Expert Panels 160
12.4 Contact Us 160
12.5 Disclaimer 160
12.6 Sources 160 1.1

List of Tables

Table 1: Stem Cell Research Market to 2017, Global Sales of Stem Cells, $bn, 2008-2014 21
Table 2: Stem Cell Research Market to 2017, Disease Conditions and Prevalence in the US, 2010 24
Table 3: Stem Cell Research Market to 2017, Preferred Countries for Stem Cell Tourism, 2011 34
Table 4: Stem Cell Research Market to 2017, Pharmaceutical Companies Partnership Environment, 2010-2011 38
Table 5: Stem Cell Research Market to 2017, Pipeline Analysis, Discovery, 2011 45
Table 6: Stem Cell Research Market to 2017, Pipeline Analysis, IND Filed, 2011 46
Table 7: Stem Cell Research Market to 2017, Pipeline Analysis, Preclinical, 2011 46
Table 8: Stem Cell Research Market to 2017, Pipeline Analysis, Phase I, 2011 49
Table 9: Stem Cell Research Market to 2017, Pipeline Analysis, Phase II, 2011 54
Table 10: Stem Cell Research Market to 2017, Pipeline Analysis, Phase III, 2011 76
Table 11: Stem Cell Research Market to 2017, the US, NIH Funding, $m, 2002-2010 83
Table 12: Stem Cell Research Market to 2017, NIH Funding, Cardiovascular, ($m), 2009-2010 84
Table 13: Stem Cell Research Market to 2017, NIH Funding, Central Nervous System, ($m), 2009-2010 86
Table 14: Stem Cell Research Market to 2017, NIH Funding, Genetic Disorders, ($m), 2009-2010 89
Table 15: Stem Cell Research Market to 2017, NIH Funding, Hematological Disorders, ($m), 2009-2010 92
Table 16: Stem Cell Research Market to 2017, NIH Funding, Oncology, ($m), 2009-2010 94
Table 17: Stem Cell Research Market to 2017, NIH Funding, Basic Research, ($m), 2009-2010 98
Table 18: Stem Cell Research Market to 2017, Segmentation of Funding Received by Therapeutic Areas, 2009 – May 2011 101
Table 19: Stem Cell Research Market to 2017, Segmentation of Funding Received by Therapeutic Areas, 2009 102
Table 20: Stem Cell Research Market to 2017, Segmentation of Funding Received by Therapeutic Areas, 2010 103
Table 21: Stem Cell Research Market to 2017, Segmentation of Funding Mechanisms by Value ($m), 2009 105
Table 22: Stem Cell Research Market to 2017, Segmentation of Funding Mechanisms by Value ($m), 2010 106
Table 23: Stem Cell Research Market to 2017, Segmentation by Funding Mechanism in Therapeutic Areas, 2010 111
Table 24: Stem Cell Research Market to 2017, Acquisitions, 2011 131
Table 25: Stem Cell Research Market to 2017, Aastrom BioSciences Inc., 2011 140
Table 26: Stem Cell Research Market to 2017, Athersys Inc., 2011 141
Table 27: Stem Cell Research Market to 2017, Osiris Therapeutics, 2011 142
Table 28: Stem Cell Research Market to 2017, Bioheart, 2011 143
Table 29: Stem Cell Research Market to 2017, Aldagen, 2011 144
Table 30: Stem Cell Research Market to 2017, Mesoblast, 2011 145
Table 31: Stem Cell Research Market to 2017, Geron, 2011 146
Table 32: Stem Cell Research Market to 2017, Advanced Cell Technology, 2011 147
Table 33: Stem Cell Research Market to 2017, Cytori Therapeutics, 2011 148
Table 34: Stem Cell Research Market to 2017, Pluristem Therapeutics, 2011 149
Table 35: Stem Cell Research Market to 2017, Medistem, 2011 150
Table 36: Stem Cell Research Market to 2017, NeoStem, 2011 151
Table 37: Stem Cell Research Market to 2017, Helix Therapeutics, 2011 152
Table 38: Stem Cell Research Market to 2017, StemCells Inc., 2011 153
Table 39: Stem Cell Research Market to 2017, University of California, San Francisco, 2011 154
Table 40: Stem Cell Research Market to 2017, University of Washington, 2011 155 1.2

 List of Figures

Figure 1: Stem Cell Research Market to 2017, Stem Cell Research and Development, 2010 12
Figure 2: Stem Cell Research Market to 2017, Current Utilization of Different Types of Stem Cells, 2010 14
Figure 3: Stem Cell Research Market to 2017, Stem Cells – Interaction Framework, 2011 15
Figure 4: Stem Cells Research Market to 2017, Cells Models –Present and the Future, 2011 16
Figure 5: Stem Cell Research Market to 2017, Unmet Need vs Time to Market, 2010-2017 17
Figure 6: Stem Cell Research Market to 2017, Applications of Stem Cell Research, 2011 18
Figure 7: Stem Cell Research Market to 2017, Global Sales of Stem Cells, $bn, 2008-2014 21
Figure 8: Stem Cell Research Market to 2017, Technology Adoption Framework, 2011 25
Figure 9: Stem Cell Research Market to 2017, Business Models in Stem Cell Industry, 2011 26
Figure 10: Stem Cell Research Market to 2017, Treatment Availability – Impact Analysis, 2011 27
Figure 11: Stem Cell Research Market to 2017, Political Environnent – Impact Analysis, 2011 28
Figure 12: Stem Cell Research Market to 2017, Advances in iPSC – Impact Analysis, 2011 29
Figure 13: Stem Cell Research Market to 2017, High Cost of Research – Impact Analysis, 2011 30
Figure 14: Stem Cell Research Market to 2017, Reimbursements – Impact Analysis, 2011 31
Figure 15: Stem Cell Research Market to 2017, Ethical, Legal and Social Issues – Impact Analysis, 2011 32
Figure 16: Stem Cell Research Market to 2017, Human Resources – Impact Analysis, 2011 33
Figure 17: Stem Cell Research Market to 2017, ASLAP Analysis of Stem Cell Tourism, 2011 35
Figure 18: Stem Cell Research Market to 2017, Federal Funding Trend, 2010 37
Figure 19: Stem Cell Research Market to 2017, PESTLE Analysis of Stem Cell Research, 2011 39
Figure 20: Stem Cell Research Market to 2017, SWOT Analysis of Stem Cell Research and Development, 2011 41
Figure 21: Stem Cell Research Market to 2017, SWOT Analysis of Stem Cell Research and Development – Impact Grid in 2010 42
Figure 22: Stem Cell Research Market to 2017, Porter’s Five Force Analysis, 2011 43
Figure 23: Stem Cell Research Market to 2017, Venture Capitalist’s Perspective on Stem Cell Research, 2011 81
Figure 24: Stem Cell Research Market to 2017, VC’s Perspective on Stem Cell Research – Impact Analysis, 2011 82
Figure 25: Stem Cell Research Market to 2017, Segmentation of Funding Received by Therapeutic Areas, 2009 – May 2011 101
Figure 26: Stem Cell Research Market to 2017, Segmentation of Funding Received by Therapeutic Areas, 2009 102
Figure 27: Stem Cell Research Market to 2017, Segmentation of Funding Received by Therapeutic Areas, 2010 103
Figure 28: Stem Cell Research Market to 2017, Segmentation of Funding Mechanisms by Value ($m), 2009 104
Figure 29: Stem Cell Research Market to 2017, Segmentation of Funding Mechanisms by Value ($m), 2010 106
Figure 30: Stem Cell Research Market to 2017, Segmentation of Total Value of Funding by Therapeutic Areas, 2009 107
Figure 31: Stem Cell Research Market to 2017, Segmentation of Total Value of Funding by Therapeutic Areas, 2010 108
Figure 32: Stem Cell Research Market to 2017, Segmentation of Total Value by the Funding Mechanisms, 2009 109
Figure 33: Stem Cell Research Market to 2017, Segmentation of Total Value by Funding Mechanisms, 2010 109
Figure 34: Stem Cell Research Market to 2017, Segmentation by Funding Mechanism in Therapeutic Areas, 2010 111
Figure 35: Stem Cell Research Market to 2017, Stem Cell Companies by Geographic Regions, 2010 113
Figure 36: Stem Cell Research Market to 2017, Country Analysis – The US 115
Figure 37: Stem Cell Research Market to 2017, Country Analysis – The UK, 2011 116
Figure 38: Stem Cell Research Market to 2017, Country Analysis- China, 2011 117
Figure 39: Stem Cell Research Market to 2017, Country Analysis – Netherlands, 2011 118
Figure 40: Stem Cell Research Market to 2017, Country Analysis – Singapore, 2011 119
Figure 41: Stem Cells Research Market to 2017, Country Analysis – South Korea, 2011 120
Figure 42: Stem Cell Research Market to 2017, Country Analysis – Japan, 2011 121
Figure 43: Stem Cell Research Market to 2017, Country Analysis – India, 2011 122
Figure 44: Stem Cell Research Market to 2017, Country Analysis – Sweden, 2011 123
Figure 45: Stem Cell Research Market to 2017, Country Analysis – Denmark, 2011 124
Figure 46: Stem Cell Research Market to 2017, Country Analysis – France, 2011 125
Figure 47: Stem Cell Research Market to 2017, Country Analysis – Germany, 2011 126
Figure 48: Stem Cells Research Market to 2017, Country Analysis – Israel, 2011 127
Figure 49: Stem Cell Research Market to 2017, Country Analysis – Australia, 2011 128
Figure 50: Stem Cell Research Market to 2017, Country Analysis – Canada, 2011 129
Figure 51: Stem Cells Research Market to 2017, Country Analysis – Czech Republic, 2011 130
Figure 52: Stem Cell Research Market to 2017, Segmentation of Licensing Deal Value by Deal Type, 2004- May 2011 132
Figure 53: Stem Cell Research Market to 2017, Segmentation of Number of Licensing Deals by Deal Type, 2004- May 2011 133
Figure 54: Stem Cell Research Market to 2017, Segmentation of Licensing Deals Value by Region, 2004 – May 2011 134
Figure 55: Stem Cell Research Market to 2017, Segmentation of Number of Licensing Deals by Region, 2004 – May 2011 135
Figure 56: Stem Cell Research Market to 2017, Segmentation of Licensing Deal Value by Region, 2004 – May 2011 136
Figure 57: Stem Cell Research Market to 2017, Segmentation of Number of Licensing Deals by Region, 2004 – May 2011 137
Figure 58: Stem Cell Research Market to 2017, Segmentation of Licensing Deal Value by Deal Type, 2004 – May 2011 138
Figure 59: Stem Cell Research Market to 2017, Segmentation of Number of Licensing Deals by Deal Type, 2004 – May 2011 139

Companies Mentioned :

Aastrom Biosciences
Athersys Inc.
Osiris Therapeutics
Bioheart
Aldagen
Mesoblast
Geron
Advanced Cell Technology
Cytori Therapeutics
Pluristem Therapeutics
Medistem
NeoStem
Helix Therapeutics
StemCells Inc.